Response to anti-EGFR therapy in chemo-refractory right-sided RAS wild-type metastatic colorectal cancer: a case report and literature review.

ABSTRACT:

Background

Anti-epidermal growth factor receptor (EGFR) therapies are important targeted agents in the treatment of metastatic colorectal cancer (CRC). However, clinical benefit is limited to patients with left-sided primary tumors and RAS wild-type (WT) disease. In right-sided chemo-refractory settings, response to anti-EGFR therapy has not been reported to date.

Case description

We present a case of a 70-year-old man with metachronous metastatic ascending colon adenocarcinoma who experienced an exceptional response to FOLFIRI (fluorouracil, leucovorin, and irinotecan) plus panitumumab after failing multiple lines of therapy. He was initially diagnosed with stage IIIB (pT4aN1M0) disease and underwent hemicolectomy followed by adjuvant FOLFOX (fluorouracil, leucovorin, and o

SUBMITTER: Xiao A 

PROVIDER: S-EPMC11921176 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature